<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666378</url>
  </required_header>
  <id_info>
    <org_study_id>15-017</org_study_id>
    <nct_id>NCT02666378</nct_id>
  </id_info>
  <brief_title>Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer</brief_title>
  <official_title>Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a
      method of detecting early signs of damage to the heart that can be associated with
      anthracycline-based chemotherapy for the treatment of breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the side effects observed in breast cancer patients receiving anthracycline-based
      treatment is heart complications in which the heart muscle is weakened and no longer able to
      pump sufficient amounts of blood throughout the body. This complication can lead to the
      following symptoms: shortness of breath on exertion, swollen ankles and feet, lack of energy
      and a reduced capacity to carry out day-to-day activities.

      This research study is focused on identifying the early signs of such heart complications
      using CMR, which may allow preventative treatment options to be made available in future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiotoxicity</measure>
    <time_frame>1 year after completion of treatment</time_frame>
    <description>Cardiotoxicity as measured by changes in left ventricular ejection fraction within one-year of completion of treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CMR/ECHO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to starting chemotherapy treatment, the participant will undergo the following procedures:
Cardiac Magnetic Resonance Imaging (CMR)
Echocardiogram (ECHO) in patients with no clinically indicated scans
Each imaging procedure will be repeated at predetermined times during the protocol
Simple blood collection for plasma biomarker analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance Imaging (CMR)</intervention_name>
    <description>Subjects will be recruited for observational cardiac magnetic resonance imaging.</description>
    <arm_group_label>CMR/ECHO</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiogram (ECHO)</intervention_name>
    <description>Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.</description>
    <arm_group_label>CMR/ECHO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Have histologic diagnosis of breast carcinoma

          -  Scheduled to receive standard clinical therapy designed by their treating oncologist

          -  Patients should receive anthracycline as part of the recommended treatment

          -  Able to give informed consent.

        Exclusion Criteria:

          -  Contraindication to contrast CMR including eGFR &lt;30 mls/min/1.73m2

          -  Uncontrolled serious concurrent illness

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Nezafat, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reza Nezafat, Ph.D</last_name>
    <phone>617-667-1747</phone>
    <email>Rnezafat@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Nezafat, Ph.D</last_name>
      <phone>617-667-1747</phone>
      <email>Rnezafat@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Reza Nezafat, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Reza Nezafat, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

